National School Choice Week Event: The State of School Choice in California in 2020

January 31, 2020
State Capitol Parking Garage, 10th Street, Sacramento, CA, USA

Join Pacific Research Institute for a policy discussion during National School Choice Week 2020


As California celebrates National School Choice Week, the future of charter schools is uncertain following legislation enacted in 2019.  Join Pacific Research Institute Senior Director of Education Studies Lance Izumi as he leads a panel of education reform experts at the State Capitol in discussing the impact of last year’s legislative changes, 2020 legislative efforts that could impact school choice, and reform ideas to preserve and expand school choice options for students and parents.


Featured Speakers:

  • Lance Izumi, Senior Director of PRI’s Center for Education

  • Larry Sand, President, California Teachers Empowerment Network

  • Assemblyman Kevin Kiley, Vice-Chair, Assembly Education Committee


Friday, January 31, 2020
12 – 1 PM
State Capitol, Room 125


Admission is free; lunch will be served

*Space is strictly limited



(function(d, s) {
var js, el = d.getElementsByTagName(s)[0];
window.BB_REG_FORM_ID = “9c1591a6-daac-4723-a81d-f4ac6f756aee”;
window.BB_REG_FORM_ENVIRONMENT_ID = “p-VFwaa-F3ZU6uSLzlD1sBnw”;
js = d.createElement(s);
js.src = “”;
el.parentNode.insertBefore(js, el);
})(document, “script”);

Tell Your Friends


Calif canstockphoto8819433

See how California's policy agenda is affecting other states

The Commerce Clause Vs. The California Progressive Agenda

Isn’t it written somewhere that one state can’t enact policies that interfere with commerce between other states? Maybe in the Constitution? Maybe in Article I, ...

Batya Ungar-Sargon – Second Class

Join us for a special episode featuring a speech by Newsweek opinion editor Batya Ungar-Sargon at a recent PRI luncheon in San Francisco. Ms. Ungar-Sargon ...
Health pina messina kfJkpeI6Lgc unsplash

Don’t Import British Methods For Rationing Access To Drugs

Earlier this year, European authorities recommended approval of tofersen, a new drug that treats a rare genetic form of amyotrophic lateral sclerosis, or ALS. That decision came ...
Scroll to Top